Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ADVM's Cash-to-Debt is ranked higher than
71% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. ADVM: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ADVM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.74  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.92
ADVM's Equity-to-Asset is ranked higher than
87% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ADVM: 0.92 )
Ranked among companies with meaningful Equity-to-Asset only.
ADVM' s Equity-to-Asset Range Over the Past 10 Years
Min: -8.98  Med: 0.92 Max: 0.96
Current: 0.92
-8.98
0.96
Interest Coverage No Debt
ADVM's Interest Coverage is ranked higher than
60% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ADVM: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ADVM' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 1.91
Beneish M-Score: 13.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -7923.30
ADVM's Operating Margin % is ranked lower than
91% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. ADVM: -7923.30 )
Ranked among companies with meaningful Operating Margin % only.
ADVM' s Operating Margin % Range Over the Past 10 Years
Min: -7923.3  Med: -4266.08 Max: -719.58
Current: -7923.3
-7923.3
-719.58
Net Margin % -7817.66
ADVM's Net Margin % is ranked lower than
91% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. ADVM: -7817.66 )
Ranked among companies with meaningful Net Margin % only.
ADVM' s Net Margin % Range Over the Past 10 Years
Min: -7817.66  Med: -4441.26 Max: -1099.17
Current: -7817.66
-7817.66
-1099.17
ROE % -47.65
ADVM's ROE % is ranked lower than
58% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. ADVM: -47.65 )
Ranked among companies with meaningful ROE % only.
ADVM' s ROE % Range Over the Past 10 Years
Min: -48.59  Med: -40.54 Max: -23.6
Current: -47.65
-48.59
-23.6
ROA % -44.69
ADVM's ROA % is ranked lower than
62% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. ADVM: -44.69 )
Ranked among companies with meaningful ROA % only.
ADVM' s ROA % Range Over the Past 10 Years
Min: -717.34  Med: -45.6 Max: -22.27
Current: -44.69
-717.34
-22.27
ROC (Joel Greenblatt) % -2975.99
ADVM's ROC (Joel Greenblatt) % is ranked lower than
74% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. ADVM: -2975.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ADVM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -45075  Med: -4399.65 Max: -2221.58
Current: -2975.99
-45075
-2221.58
GuruFocus has detected 4 Warning Signs with Adverum Biotechnologies Inc $ADVM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ADVM's 10-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ADVM Guru Trades in Q1 2016

Paul Tudor Jones 19,422 sh (New)
Jim Simons 278,700 sh (+239.46%)
» More
Q2 2016

ADVM Guru Trades in Q2 2016

Chuck Royce 193,346 sh (New)
PRIMECAP Management 423,900 sh (New)
Jim Simons 735,137 sh (+163.77%)
Paul Tudor Jones Sold Out
» More
Q3 2016

ADVM Guru Trades in Q3 2016

Jim Simons 1,004,400 sh (+36.63%)
PRIMECAP Management 426,300 sh (+0.57%)
Chuck Royce 92,346 sh (-52.24%)
» More
Q4 2016

ADVM Guru Trades in Q4 2016

Chuck Royce Sold Out
PRIMECAP Management 425,600 sh (-0.16%)
Jim Simons 969,700 sh (-3.45%)
» More
» Details

Insider Trades

Latest Guru Trades with ADVM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ARWR, OTCPK:TBGNF, NAS:PRQR, NAS:GEMP, NAS:APEN, NAS:CDTX, AMEX:PFNX, NAS:EGLT, NAS:MRTX, NAS:VVUS, OTCPK:NURPF, NAS:GLYC, OTCPK:IMMVF, NYSE:KDMN, NAS:CBAY, NAS:NVIV, OTCPK:BNRPF, AMEX:XXII, NAS:CRME, NAS:AGTC » details
Traded in other countries:AVU.Germany,
Headquarter Location:USA
Adverum Biotechnologies Inc is a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye.

Adverum Biotechnologies Inc is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. The Company has leveraged next-generation gene therapy platform to create a pipeline of product candidates. Their product candidates are designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing gene therapeutics. Th Companies competitors include companies like MeiraGTx, Dimension Therapeutics, Inc., Voyager Therapeutics, Audentes Therapeutics, AveXis, REGENXBIO Biosciences, 4D Molecular Therapeutics, Applied Genetic Technologies Corporation and uniQure. The Company is regulated by FDA.

Top Ranked Articles about Adverum Biotechnologies Inc

Adverum Biotechnologies, Inc. Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors
Adverum Biotechnologies Announces Updated Presentation Time for ARM 5th Annual Cell & Gene Therapy Investor Day
Adverum Biotechnologies to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
Adverum Biotechnologies, Inc. Appoints Patrick Machado, J.D. to Board of Directors

-- Mr. Machado to Chair Audit Committee -- MENLO PARK, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, today announced the appointment of Patrick Machado, J.D. to its board of directors. Mr. Machado will be the chairman of the audit committee. “Pat is an experienced board member and executive who has led finance, business development and legal functions for two decades at biopharmaceutical companies, spanning development to commercial stage. We look forward to benefitting from his energy and extensive background,” said Paul Cleveland, executive chairman of the board of Adverum.  “Adverum has begun a new phase as a company, with a new board and executive leadership, a robust pipeline, and a platform of industry-leading technology all coming together as we advance toward becoming a clinical-stage company by the end of this year.” Mr. Machado has 20 years of experience with biopharmaceutical companies leading finance, business development, and legal functions. In addition to being a qualified financial and legal expert, he has a broad business background. Most recently, he was a co-founder of Medivation, Inc. and served as its chief business officer from 2009 to 2014, as its chief financial officer from 2004 until his retirement in 2014, and as a member of its board of directors from April 2014 until its acquisition by Pfizer in September 2016. From 1998 to 2001, Mr. Machado worked with ProDuct Health, Inc. as senior vice president, chief financial officer and earlier as general counsel. Upon ProDuct Health’s acquisition by Cytyc Corporation, he served as a consultant to Cytyc to assist with transitional matters from 2001 to 2002. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado received a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University. Mr. Machado also serves as a member of the board of directors at Armaron Bio, Chimerix, Inc., Inotek Pharmaceuticals Corporation, Roivant Sciences, and SCYNEXIS, Inc. At Chimerix and Inotek, Mr. Machado serves as a member of the audit committees. About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com. Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Adverum’s plans, potential opportunities, expectations, projections, goals, objectives, milestones, strategies and product pipeline, all of which are based on certain assumptions made by Adverum on current conditions, expected future developments and other factors Adverum believes are appropriate in the circumstances. Adverum may not consummate any plans or product or clinical development goals in a timely manner, or at all, or otherwise carry out the intentions or meet the expectations or projections disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that Adverum’s resources will not be sufficient for Adverum to conduct or continue planned development programs and planned clinical trials, the risk of a delay in the enrollment of patients in Adverum’s clinical studies or in the manufacturing of products to be used in such clinical studies, and the risk that Adverum will not be able to successfully develop or commercialize any of its product candidates. Risks and uncertainties facing Adverum are described more fully in Adverum’s periodic reports filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contacts for Adverum:

Leone Patterson
Chief Financial Officer
Adverum Biotechnologies, Inc.
650-665-7222
[email protected]

Jill Steier
Senior Vice President
The Trout Group LLC
646-378-2946
[email protected]

Read more...
Value Screeners Identify Cheap Company Stocks Technology and health care sectors offer bargain investments
As discussed in a previous article, the value screeners offer helpful investing insights. Not only do the screeners list good company stocks in which to invest, they can also identify which stock markets are undervalued. Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.52
ADVM's PB Ratio is ranked higher than
98% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ADVM: 0.52 )
Ranked among companies with meaningful PB Ratio only.
ADVM' s PB Ratio Range Over the Past 10 Years
Min: 0.41  Med: 0.79 Max: 8.97
Current: 0.52
0.41
8.97
PS Ratio 64.29
ADVM's PS Ratio is ranked lower than
81% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. ADVM: 64.29 )
Ranked among companies with meaningful PS Ratio only.
ADVM' s PS Ratio Range Over the Past 10 Years
Min: 33.94  Med: 97.64 Max: 1518.85
Current: 64.29
33.94
1518.85
EV-to-EBIT 0.95
ADVM's EV-to-EBIT is ranked higher than
88% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. ADVM: 0.95 )
Ranked among companies with meaningful EV-to-EBIT only.
ADVM' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.8  Med: 0.8 Max: 3.1
Current: 0.95
-25.8
3.1
EV-to-EBITDA 0.96
ADVM's EV-to-EBITDA is ranked higher than
89% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. ADVM: 0.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
ADVM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.9  Med: 0.8 Max: 3.1
Current: 0.96
-25.9
3.1
Current Ratio 22.76
ADVM's Current Ratio is ranked higher than
94% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ADVM: 22.76 )
Ranked among companies with meaningful Current Ratio only.
ADVM' s Current Ratio Range Over the Past 10 Years
Min: 0.46  Med: 22.76 Max: 39.7
Current: 22.76
0.46
39.7
Quick Ratio 22.76
ADVM's Quick Ratio is ranked higher than
94% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ADVM: 22.76 )
Ranked among companies with meaningful Quick Ratio only.
ADVM' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 22.76 Max: 39.7
Current: 22.76
0.46
39.7
Days Sales Outstanding 222.26
ADVM's Days Sales Outstanding is ranked lower than
92% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. ADVM: 222.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
ADVM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.08  Med: 41.42 Max: 222.26
Current: 222.26
6.08
222.26

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.56
ADVM's Price-to-Net-Cash is ranked higher than
99% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. ADVM: 0.56 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ADVM' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.56  Med: 0.99 Max: 8.36
Current: 0.56
0.56
8.36
Price-to-Net-Current-Asset-Value 0.55
ADVM's Price-to-Net-Current-Asset-Value is ranked higher than
99% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. ADVM: 0.55 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ADVM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.55  Med: 0.99 Max: 8.31
Current: 0.55
0.55
8.31
Price-to-Tangible-Book 0.53
ADVM's Price-to-Tangible-Book is ranked higher than
98% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ADVM: 0.53 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ADVM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.53  Med: 0.97 Max: 8.22
Current: 0.53
0.53
8.22
Price-to-Median-PS-Value 0.63
ADVM's Price-to-Median-PS-Value is ranked higher than
75% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ADVM: 0.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ADVM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63  Med: 1.03 Max: 12.39
Current: 0.63
0.63
12.39
Earnings Yield (Greenblatt) % 105.26
ADVM's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ADVM: 105.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ADVM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 32.5  Med: 94.9 Max: 916.3
Current: 105.26
32.5
916.3

More Statistics

Revenue (TTM) (Mil) $1.46
EPS (TTM) $ -3.16
Short Percentage of Float2.41%
52-Week Range $2.50 - 6.31
Shares Outstanding (Mil)42.06
» More Articles for ADVM

Headlines

Articles On GuruFocus.com
Adverum Biotechnologies, Inc. Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors Apr 20 2017 
Adverum Biotechnologies Announces Updated Presentation Time for ARM 5th Annual Cell & Gene Therapy I Apr 17 2017 
Adverum Biotechnologies to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day Apr 06 2017 
Adverum Biotechnologies, Inc. Appoints Patrick Machado, J.D. to Board of Directors Mar 14 2017 
Value Screeners Identify Cheap Company Stocks Aug 29 2016 
5 of the Most Discounted U.S. Listed Net-Nets Mar 30 2016 
5 Deep Value or Net-Net Investment Ideas Feb 09 2016 
PRIMECAP's 3rd-Quarter Increases That Exceeded 100% Jan 13 2016 
AVALANCHE 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General a Sep 04 2015 
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Avalan Sep 04 2015 

More From Other Websites
Adverum Biotechnologies, Inc. Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors Apr 20 2017
Adverum Biotechnologies Announces Updated Presentation Time for ARM 5th Annual Cell & Gene Therapy... Apr 17 2017
ETFs with exposure to Adverum Biotechnologies, Inc. : April 12, 2017 Apr 12 2017
Adverum Biotechnologies to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day Apr 06 2017
Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
Adverum Biotechnologies, Inc. Appoints Patrick Machado, J.D. to Board of Directors Mar 14 2017
Adverum Biotechnologies posts 4Q loss Mar 06 2017
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2016 Financial Results and Provides... Mar 06 2017
Adverum (ADVM) to Post Q4 Earnings: What's in the Cards? Feb 27 2017
Adverum Biotechnologies to Present at Upcoming Investor Conferences Feb 21 2017
Is KCAP Financial Inc (KCAP) A Good Stock to Buy? Dec 19 2016
Is Osiris Therapeutics, Inc. (OSIR) A Good Stock To Buy? Dec 18 2016
Is Adverum Biotechnologies Inc (ADVM) a Good Stock to Buy? Dec 14 2016
ETFs with exposure to Adverum Biotechnologies, Inc. : December 5, 2016 Dec 05 2016
Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28,... Nov 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)